tbuckley/cabot-search huggingface dataset:
SAT0088 Anti-JAK Is Anti-Fibrotic in Patients with Rheumatoid Arthritis
Authors: S. Hirata, N.S. Gudmann, S. Kubo, M. Karsdal, A.C. Bay-Jensen, Y. Tanaka
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To quantify connective tissue turnover from type III collagen in response to 4 different types of intervention in rheumatoid arthritis (RA); methotrexate (MTX) combined with or without either tocilizumab (TCZ), tofacitinib (TOFA) or adalimumab (ADA) in RA. <h3>Methods</h3> 149 RA patients were treated with 1) MTX; 23, 2) ADA+MTX; 49, 3) TOFA+MTX; 27 or 4) TCZ+MTX; 50. Four specific neo-epitopes biomarkers were measured in the serum samples; C3M and PRO-C3 markers of type III collagen degradation and formation respectively. <h3>Results</h3> Tissue destruction measured by C3M increased in RA patients and was significantly correlated with total sharp score (SHS) as well as disease activity (DAS28) at baseline even after adjustment for covariates (rho=0.20, 0.33, p=0.018, &lt;0.0001, respectively). PRO-C3 was also increased and the levels correlated with both SHS, and DAS28 (rho=0.22, 0.43, p=0.0067, &lt;0.0001, respectively). Tissue destruction measured by C3M was reversed to healthy levels in all treatment after the treatment with MTX, ADA+MTX, TOFA+MTX or TCZ+MTX. However, JAK inhibition resulted in a decrease of PRO-C3, a sign of fibrogenesis, whereas MTX increased PRO-C3 in RA. (Figure) <h3>Conclusions</h3> Interstitial tissue remodeling was increased in RA as compared to healthy controls. All four different intervention inhibited inflammation-driven tissue destruction to the same level, whereas only TOFA blocked fibrogenesis in RA patients, indicating that JAK inhibition could attenuate tissue fibrosis. <h3>Disclosure of Interest</h3> S. Hirata Speakers bureau: AbbVie, Eisai, Bristol Meyers Squibb, N. Gudmann Employee of: Nordic Bioscience A/S, S. Kubo: None declared, M. Karsdal Shareholder of: Nordic Bioscience A/S, Employee of: Nordic Bioscience A/S, A. Bay-Jensen Employee of: Nordic Bioscience A/S, Y. Tanaka Grant/research support from: Mitsubishi-Tanabe, Chugai, MSD, Astellas, Novartis, Speakers bureau: Abbvie, Chugai, Astellas, Takeda, Santen, Mitsubishi-Tanabe, Pfizer, Janssen, Eisai, Daiichi-Sankyo, UCB, GlaxoSmithKline, Bristol-Myers
Late Onset Hemorrhagic Cystitis (LOHC) Following Stem Cell Transplant (SCT): Risk Factors and Outcomes.
Authors: Nasser Janbay, Albish Amin, N. Visweshar, Rakesh Ojha, Reyad Mohsen, Devinderdal Randhawa, S. Stives, H. Benn, Pradeep Manna, Rajneesh Nath
Journal: Blood (2004)
Induction of Growth Inhibition and Apoptosis by TZD18, a Novel Dual Ligand for PPAR alpha/gamma, in Human Ph-Positive ALL Cells In Vitro.
Authors: Elena Elstner, Hongyu Liu, Chuanbing Zang, Dachuan Liu, Shunnan Xu, Martin H. Fenner, Kurt Possinger
Journal: Blood (2004)
Patterns and Timing of Initial Relapse in Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma.
Authors: Sughosh Dhakal, Tithi Biswas, Sheema Chawla, Nikhil Uppal, Christopher Beck, Sarada Uppuluri, Jane Liesveld, Ann Muhs, Gordon Phillips, Louis Constine
Journal: Blood (2006)
T-Cell Profiling Shows Marked Differences in Gene Expression Between Tumour Infiltrating (TIL) and Peripheral Blood (PB) Antibody-Bead Selected T-Cells From Fresh Lymph Node and PB Samples in Follicular Non-Hodgkin's Lymphoma (FL): Possible implications for Immunomodulatory Therapy
Authors: Saad M B Rassam, Farooq Malik, John Schofield, Haytham Ali, Ghulam J. Mufti
Journal: Blood (2012)
PTH-142 Gastrointestinal Malignancy Not Detected On CT Scanning
Authors: HL Lee, S Peterson, AM Verma
Journal: Gut (2016)

<h3>Introduction</h3> The British Society of Gastroenterology (BSG) guideline on the management iron deficiency anaemia advocates the use of unprepared CT scans for patients who are elderly frail or have significant co-morbidity (in those not suitable for endoscopy). The guideline does state that unprepared CT may miss cancerous lesions. Despite this, CT scanning is regularly used as a diagnostic modality for gastrointestinal (GI) cancer. We have data of CT reports of patients with endoscopically diagnosed upper GI (UGI) and lower GI (LGI) cancers from 2014–2015 in Kettering General Hospital (KGH). We are auditing the proportion of GI cancers not detectable on CT scans. <h3>Methods</h3> Data was analysed between January 1<sup>st</sup> 2014 to December 31<sup>st</sup> 2015 from endoscopy and radiology reporting systems to see what proportion of cancers were not detectable on CT scans. This covers two cohorts, patients (with GI cancers) with unprepared CT (days after index endoscopy) and patients that had their CT immediately post endoscopy (same-day – hence fasted pre-endoscopy for UGI endoscopy and prepared colons for LGI endoscopy). <h3>Results</h3> Values represent cancers not detectable on CT scans. Unprepared CT: LGI cancers 2 out of 78 (2.56%), UGI cancers 2 out of 29 (6.90%) Prepared CT: LGI cancers 7 out of 68 (10.29%), UGI cancers 0 out of 25 All CTs: LGI cancers 9 out of 146 (6.16%, 95% CI 3.23–11.15%) UGI cancers 2 out of 54 (3.70%, 95% CI 1.02–12.54%) All cancers 11 out of 200 (5.50%, 95% CI 3.10–9.58%) <h3>Conclusion</h3> Our audit shows that whilst CT scanning picks up the vast majority of endoscopically detected GI cancers, 6.16% of LGI and 3.70% of UGI cancers are not detected on CT. This rate isn’t improved in the prepared CT cohort (having CT immediately post endoscopy). Overall, 11 out of 200 cancers were not detected on CT (5.50% 95% CI 3.10–9.58%). Clinicians need to bear this in mind when using CT scanning to diagnose/rule out GI cancers. <h3>Reference</h3> 1 Goddard AF, James MW, McIntyre, AS, Scott BB, on behalf of the British Society of Gastroenterology. Guidelines for the management of iron deficiency Anaemia. <i>Gut</i> 2011;<b>60</b>:1309-1316. doi:10.1136/gut.2010.228874 <h3>Disclosure of Interest</h3> None Declared
Mitochondrial dysfunction in cancer chemoprevention by phytochemicals from dietary and medicinal plants
Authors: Anuradha Sehrawat, Ruchi Roy, Subrata K. Pore, Eun-Ryeong Hahm, Suman K. Samanta, Krishna B. Singh, Su-Hyeong Kim, Kamayani Singh, Shivendra V. Singh
Journal: Seminars in Cancer Biology (2016)
AB0840 Association between Catechol-O-Methyl Transferase Gene Polymorphisms and fibromyalgia in A Korean Population: A Case-Control Study
Authors: J.-H. Kang, D.-J. Park, S.-H. Kim, S.-S. Nah, J.H. Lee, S.-K. Kim, Y.-A. Lee, S.-J. Hong, H.-S. Kim, H.-S. Lee, H.A. Kim, C.-I. Joung, S.-H. Kim, S.-S. Lee
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Although polymorphisms of the catechol-O-methyl transferase (COMT) gene have been implicated in altered pain sensitivity, results concerning the association between COMT gene polymorphisms and FM are equivocal. We assessed the associations between COMT single-nucleotide polymorphisms (SNP) and FM risk and symptom severity. <h3>Methods</h3> In total, 409 FM patients and 423 controls were enrolled. Alleles and genotypes at five positions [rs6269 (A&gt;G), rs4633 (C&gt;T), rs4818 (C&gt;G), rs4680 (C&gt;G) and rs165599 (A&gt;G)] in the COMT gene were genotyped from peripheral blood DNA. <h3>Results</h3> Alleles and genotypes of the rs4818 COMT gene polymorphism were significantly associated with increased susceptibility to FM. The rs4818 GG genotype was more strongly associated with FM compared to the CC genotype (OR =1.680, 95% CI: 1.057, 2.672, P=0.027). Although allele and genotype frequencies did not differ among groups, the rs4633 CT genotype was not associated with the presence of FM following adjustment for age and sex (OR =0.745; 95% CI: 0.558, 0.995; P=0.046). However, no association was observed between clinical measures and individual COMT SNPs. In haplotype analysis, there was a significant association between ACG haplotype and FM susceptibility sex (OR =2.960, 95% CI: 1.447, 6.056, P=0.003) and the number of tender points (P=0.046). <h3>Conclusions</h3> This large-scale study suggests that polymorphisms of the COMT gene may be associated with FM risk and pain sensitivity in Korean FM patients. However, our results differed to those of previous studies, suggesting ethnic variation in COMT gene polymorphisms in FM. <h3>Disclosure of Interest</h3> None declared
Efficacy of Lenalidomide in Patients with Multiple Myeloma Previously Treated by Melphalan-Prednisone and Thalidomide
Authors: Jessica Michel, Sabine Revuz, Stéphanie Tardy, Guillemette Fouquet, Murielle Roussel, Oana Balasanu, Serge Bologna, Caroline Bonmati, Aurore Perrot, Dana Ranta, Pierre Feugier, Michel Attal, Xavier Leleu, Thierry Facon, Cyrille Hulin
Journal: Blood (2012)
Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group.
Authors: Thomas Elter, Rojin James, Stephan Stilgenbauer, Sebastian Boettcher, Matthias Ritgen, Hartmut Doehner, Michael Hallek, Andreas Engert
Journal: Blood (2009)
A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
Authors: Andrew M. Evens, Julie M Vose, Wael Harb, Leo I. Gordon, Robert Langdon, Barbara Grant, Julian Sprague, Clara Plasencia, Mint Sirisawad, Jeanne Yue, Ying Luan, Aaron Siek, Lei Zhou, Sriram Balasubramanian, Nancy L. Bartlett
Journal: Blood (2012)
Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin
Authors: Yi-Hsin Chan, Yung-Hsin Yeh, Lai-Chu See, Chun-Li Wang, Shang-Hung Chang, Hsin-Fu Lee, Lung-Sheng Wu, Hui-Tzu Tu, Chi-Tai Kuo
Journal: Journal of the American College of Cardiology (2016)

Whether dabigatran is associated with a lower risk of acute kidney injury (AKI) in patients with nonvalvular atrial fibrillation (NVAF) remains unknown. The authors compared the risk of AKI in Asians with NVAF who were prescribed dabigatran versus warfarin. The authors analyzed patients enrolled in the Taiwan nationwide retrospective cohort study from June 1, 2012, to December 31, 2013. Dabigatran and warfarin were taken by 7,702 and 7,885 NVAF patients without a history of chronic kidney disease (CKD) and 2,256 and 2,089 NVAF patients with a history of CKD, respectively. A propensity-score weighted method was used to balance covariates across study groups. A total of 6,762 (88%) and 940 (12%) CKD-free patients and 2,025 (90%) and 231 (10%) CKD patients took dabigatran 110 mg and 150 mg twice daily, respectively. Dabigatran was associated with a lower risk of AKI than warfarin for either the CKD-free (hazard ratio [HR]: 0.62; 95% confidence interval [CI]: 0.49 to 0.77; p < 0.001) or CKD (HR: 0.56; 95% CI: 0.46 to 0.69; p < 0.001) cohort. As the increment in CHA2DS2-VASc score (a risk score based on congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, aged 65 to 74 years, and female sex) increased from 0/1 to 6+ points, the incidence of AKI for the dabigatran group was relatively stable (1.87% to 2.91% per year for the CKD-free cohort; 7.31% to 13.15% per year for the CKD cohort) but increased obviously for patients taking warfarin for either CKD-free (2.00% to 6.16% per year) or CKD cohorts (6.82 to 26.03% per year). The warfarin group had a significantly higher annual risk of AKI than the dabigatran group for those with a high CHA2DS2-VASc score (≥4 for the CKD-free cohort and ≥3 for the CKD cohort). Subgroup analysis revealed that among dabigatran users, those taking either low-dose or standard-dose dabigatran, those with a warfarin-naïve or warfarin-experienced history, those with or without diabetes, and those with CHA2DS2-VASc ≥4 or HAS-BLED ≥3 (risk score based on hypertension, abnormal renal and liver function, stroke, prior major bleeding, labile international normalized ratios, age 65 years or older, drugs or alcohol usage history) all had a lower risk of AKI than those taking warfarin. Among Asians with NVAF, dabigatran is associated with a lower risk of AKI than warfarin.
SAT0054 Favorable Long-Term Outcome of Early Inflammatory Arthritis in Clinical Practice: High Baseline Haq and Das28 at 3 Months Predict Use of Biologics
Authors: A. Fanouriakis, I. Papalopoulos, E. Gergianaki, G. Spyrou, P. Rapsomaniki, M. Terizaki, N. Avgoustidis, A. Repa, D.T. Boumpas, P. Sidiropoulos
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The course and natural history of early inflammatory arthritis (EA) varies widely and partly depends on the level of disease control in the early stages. Dedicated EA clinics follow a systematic targeted approach to improve long-term outcome of patients. <h3>Objectives</h3> To assess the long-term outcome of EA following care in a dedicated early arthritis outpatient clinic. <h3>Methods</h3> The "Early Arthritis (EA) Cohort" of the Department of Rheumatology of the University Hospital of Crete is a prospective cohort, which follows patients with inflammatory arthritis [RA, spondylarthritis or undifferentiated (UA)] of less than 6 months duration. Patients are followed quarterly for 2 years with systematic documentation of disease activity and function (measured by the DAS28 and HAQ, respectively), as well as for changes in therapy based on physician judgment. For the purpose of this study, we assessed long-term outcome (disease activity and function at 2 years) and examined prognostic factors for subsequent initiation of biologic agent. <h3>Results</h3> Out of 559 patients referred to the EA Clinic, a total of 317 had a final diagnosis of RA or UA and were included in the present analysis [83.0% women, mean (SD) age at disease diagnosis 53.7 (15.1) years, 28.5% positive for RF or/and ACPA, mean (SD) number of tender and swollen joints at baseline 6.9 (6.0) and 5.5 (5.5), respectively. Mean (SD) DAS 28 at baseline was 4.59 (1.38) and mean HAQ was 0.59 (0.51), with 33.9% of patients having high disease activity (DAS28&gt;5.1) and 18.3% reporting a HAQ≥1. At 2 years of follow-up, mean (SD) DAS28 and HAQ were 3.63 (1.3) and 0.49 (0.48), respectively (p&lt;0.001 compared to baseline values for both). Nevertheless, 38.3% of patients still had moderate and 13.8% high disease activity at 2 years, while 19.3% reported a HAQ&gt;0.75. During the course of follow-up, 34 patients received a biologic agent due to persistent high disease activity. In multivariate regression analysis, factors associated with initiation of biologic were HAQ at baseline [adjusted RR (95% CI) 4.91 (3.54–6.81)] and DAS28 at 3 months [adjusted RR (95% CI) 1.49 (1.15–1.93)]. <h3>Conclusions</h3> Routine care with regular, objective documentation of disease activity and function is associated with satisfactory long-term outcomes in early inflammatory arthritis. Baseline impaired function and persistent disease activity at 3 months predict need for biologic treatment during follow-up. <h3>Disclosure of Interest</h3> None declared
Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients
Authors: Farrukh T Awan, John M. Pagel, Leslie A Andritsos, Ajay K. Gopal, Richard R. Furman, Stephen Spurgeon, Delva Deauna-Limayo, Scott Stromatt, John C. Byrd
Journal: Blood (2011)
Five minutes with . . . Peter Fleming
Authors: Susan Mayor
Journal: BMJ (2016)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Five minutes with . . . Peter Fleming Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Intravenous Busulphan in Combination with ETOPOSIDE and MELPHALAN Used as Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Lymphomas: Evaluation of Toxicity and Efficacy
Authors: Despina Mallouri, Ioanna Sakellari, Ioannis Batsis, Varnavas Konstantinou, Panayotis Baliakas, Athanasios Antoniou, Chrisa Apostolou, Achilles Anagnostopoulos, Athanasios Fassas
Journal: Blood (2010)
Endothelial Microparticles and Their Binding to Leukocytes in Patients with End-Stage Renal Disease.
Authors: David Zuckerman, Mark Hofmeyer, Julio A. Chirinos, Wenche Jy, Joaquin J. Jimenez, Lawrence L. Horstman, Vicente F. Corrales-Medina, Philip Pennel, Yeon-Soong Ahn
Journal: Blood (2006)
Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.
Authors: Francesc Bosch, Pau Abrisqueta, Neus Villamor, Maria Jose Terol, Josep-Maria Ribera, Eva Gonzalez-Barca, Marcos Gonzalez, Eugenia Abella, Julio Delgado, Yolanda Gonzalez, Secundino Ferrer, Felix Carbonell, Lourdes Escoda, Isidro Jarque, Encarnacion Monzo, Ana Muntañola, Olga Salamero, Emili Montserrat
Journal: Blood (2008)
Phenotypic Examination of Side Population (SP) Cells in Highly Enriched Human CD34+ Cells Obtained from Peripheral Blood Progenitor Cells (PBPC) and Bone Marrow.
Authors: Dag Josefsen, Leiv S. Rusten, Trond Stokke, Lise Forfang, Erlend B. Smeland, Gunnar Kvalheim
Journal: Blood (2004)
Long-Term Follow up of Pediatric Patients with Hodgkin Lymphoma Treated with High Dose Therapy and Autologous Stem Cell Transplantation
Authors: Lisa Giulino Roth, Tara O'Donohue MD, Tanya Trippett, Elizabeth Klein, Nancy A. Kernan, Rachel Kobos, Susan Prockop, Andromachi Scaradavou, Neerav Shukla, Peter G Steinherz, Alison J Moskowitz, Craig H. Moskowitz, Farid Boulad
Journal: Blood (2015)
Prognostic impact of the putative cancer stem cell markers <scp>ABCG</scp> 2, <scp>CD</scp> 133, <scp>ALDH</scp> 1A1 and <scp>CD</scp> 44V7/8 in metastatic melanoma
Authors: L. Speigl, N. Janssen, B. Weide, G. Pawelec, C. Shipp
Journal: British Journal of Dermatology (2016)

Despite recent therapeutic advances, a diagnosis of metastatic melanoma still foreshadows a grim prognosis for the majority of patients. One of the factors believed to be associated with the failure of current conventional cancer therapies are the so-called Cancer Stem Cells (CSCs). CSCs share common features with corresponding tissue stem cells, such as self-renewal capacity and the ability to give rise to progeny with the potential to proliferate and differentiate. Therapeutically targeting CSCs may thus eliminate the root cause of the cancer, however this would require the accurate identification of markers distinguishing CSCs from normal cells. The expression of candidate CSC markers is associated with a poor prognosis in a number of cancer types, but their clinical significance remains unclear and to the best of knowledge there have been no clinical studies in melanoma. Here, we aimed to determine the clinical significance of four molecules identifying putative CSCs, namely CD133, ABCG2, ALDH1A1 and CD44v7/8.

This article is protected by copyright. All rights reserved.
Gamma-Globin Gene Expression in Adult Human Erythroblasts Is Associated with Concurrent Changes in the Nuclear Protein Levels of at Least Seven Transcription Factors.
Authors: Orapan Sripichai, Y. Terry Lee, Toshihiko Tanno, Seung-Jae Noh, Colleen Byrnes, Emily Riehm Meier, Jeffery L Miller
Journal: Blood (2008)
French-Brazilian Survey On Pregnancy in Sickle Cell Disease A Study of the International Sickle Cell Disease Observatory
Authors: Jean-Antoine Ribeil, Patrícia Santos Ressende Cardoso, Aurelie Stanislas, Vanessa Maria Fenelon Costa, Benjamin Deloison, Milza Cintra Januario, Caroline Charlier, Laia Batlle, Yves Ville, Yves Dumez, Frederic Galacteros, Olivier Lortholary, Alexandra Benachi, Jean-Marc Treluyer, Annalisa Ruggeri, Marcos Borato Viana, Eliane Gluckman, Vanderson Rocha, Marina Cavazzana-Calvo, Regina Amélia Lopes Pessoa de Aguiar
Journal: Blood (2012)
Single and Codon-Optimized Synonymous Mutations in Factor IX Alter Protein Properties
Authors: Sandra C. Tseng, Nobuko H. Katagiri, Vijaya L. Simhadri, Sujata Jha, Nathan C. Edwards, David B. Kopelman, Zuben E. Sauna, Michael Z. Stern, Ran Zichel, Anton A. Komar, Chava Kimchi-Sarfaty
Journal: Blood (2011)
Early CPAP versus Surfactant in Extremely Preterm Infants
Journal: New England Journal of Medicine (2010)

Background There are limited data to inform the choice between early treatment with continuous positive airway pressure (CPAP) and early surfactant treatment as the initial support for extremely-low-birth-weight infants. Methods We performed a randomized, multicenter trial, with a 2-by-2 factorial design, involving infants who were born between 24 weeks 0 days and 27 weeks 6 days of gestation. Infants were randomly assigned to intubation and surfactant treatment (within 1 hour after birth) or to CPAP treatment initiated in the delivery room, with subsequent use of a protocol-driven limited ventilation strategy. Infants were also randomly assigned to one of two target ranges of oxygen saturation. The primary outcome was death or bronchopulmonary dysplasia as defined by the requirement for supplemental oxygen at 36 weeks (with an attempt at withdrawal of supplemental oxygen in neonates who were receiving less than 30% oxygen). Results A total of 1316 infants were enrolled in the study. The rates of the primary outcome did not differ significantly between the CPAP group and the surfactant group (47.8% and 51.0%, respectively; relative risk with CPAP, 0.95; 95% confidence interval [CI], 0.85 to 1.05) after adjustment for gestational age, center, and familial clustering. The results were similar when bronchopulmonary dysplasia was defined according to the need for any supplemental oxygen at 36 weeks (rates of primary outcome, 48.7% and 54.1%, respectively; relative risk with CPAP, 0.91; 95% CI, 0.83 to 1.01). Infants who received CPAP treatment, as compared with infants who received surfactant treatment, less frequently required intubation or postnatal corticosteroids for bronchopulmonary dysplasia (P<0.001), required fewer days of mechanical ventilation (P=0.03), and were more likely to
Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial
Authors: Nancy L. Bartlett, Betsy R. LaPlant, Jing Qi, Stephen M. Ansell, John G. Kuruvilla, Craig B. Reeder, Lim S. Thye, Daniel M. Anderson, Charles Erlichman, Barry A. Siegel
Journal: Blood (2014)
New Yellow Plaques in a Patient Taking Pembrolizumab
Authors: Paul R. Massey, Krystal M. Jones, Matthew C. Fox
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal